Healthcare
SciSparc Ltd.(SPRC)
Live Price
Offline$7.41
-7.84% today
1Y Change
-86.93%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- -54.6%
- EPS Growth
- +91.4%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SciSparc Ltd. (SPRC) is a Healthcare stock with listed on NASDAQ. The stock last traded around $7.41 and down 86.9% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -54.6%, EPS growth of +91.4%, a dividend yield of 0.0%. What stands out right now is revenue -54.6%, EPS +91.4%, free cash flow +13.3% with operating margin -2156.9% and ROIC -782.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPRC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-54.6% vs +7.6% peer median
Operating Margin
Below sector median
-2156.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -54.6% and EPS is at +91.4%, with operating margin around -2156.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +1.7% | +33.3% | -36.2% |
2025 Jul 24, 2025 | โ | -5.6% | -25.6% | -45.0% |
2025 Apr 24, 2025 | โ | +5.7% | +3.7% | +30.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPRC
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SPRC Max Drawdown
-95.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SPRC and SPY.
Company Overview
SciSparc Ltd.
NASDAQ Capital Market
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
- Leadership
- Oz Adler
- IPO Date
- Aug 30, 2021
- Employees
- 2
- Street Address
- Tower A
- Mailing
- Tel Aviv, 6971916
- Region
- Tel Aviv, IL
- Reporting Currency
- USD
- Investor Line
- 972 3 715777
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.5
- Price/Book
- โ
Growth
- Revenue
- -54.6%
- EPS
- +91.4%
- Free Cash Flow
- +13.3%
Profitability
- Gross Margin
- 21.9%
- Operating Margin
- -2156.9%
- Net Margin
- -1312.8%
- ROE
- -330.2%
- ROIC
- -782.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.55
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.